Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × B3(Fv)-PE38KDEL recombinant immunotoxin × Clear all
NCT00085150 2015-04-30

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled
DermatologicLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Leukemia, Lymphoma, Mycosis Fungoides, Recurrence, Sezary Syndrome, Leukemia, Biphenotypic, Acute, Lymphoma, T-Cell, Cutaneous, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating